Selection of a respiratory syncytial virus fusion inhibitor clinical candidate, part 1: Improving the pharmacokinetic profile using the structure-property relationship

Journal of Medicinal Chemistry

Volumn 50, Issue 19, 2007, Pages 4572-4584

  Bonfanti, Jean François ^a   Doublet, Frédéric ^a   Fortin, Jérôme ^a   Lacrampe, Jean ^a   Guillemont, Jérôme ^a   Muller, Philippe ^a   Queguiner, Laurence ^a   Arnoult, Eric ^a   Gevers, Tom ^b   Janssens, Peggy ^b   Szel, Heidi ^b   Willebrords, Rudy ^b   Timmerman, Philip ^b   Wuyts, Koen ^b   Janssens, Frans ^b   Sommen, Cois ^b   Wigerinck, Piet ^c   Andries, Koen ^b  

^a JOHNSON AND JOHNSON   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^c TIBOTEC BVBA   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4,6 DIMETHYL 2 (3 MORPHOLIN 4 YLPROPYLAMINO)BENZOIMIDAZOL 1 YLMETHYL] 6 METHYLPYRIDIN 3 OL; 3 [1 (3 HYDROXY 6 METHYLPYRIDIN 2 YLMETHYL) 4,6 DIMETHYL 1H BENZOIMIDAZOL 2 YLAMINO]PROPANE 1,2 DIOL; AMINE; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; JNJ 2408068; PIPERIDINE; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; VIRUS FUSION PROTEIN; VIRUS FUSION PROTEIN INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DOG; DRUG HALF LIFE; DRUG RETENTION; DRUG STRUCTURE; DRUG SYNTHESIS; MALE; MONKEY; NONHUMAN; PKA; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; REACTION ANALYSIS; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; SPRAGUE DAWLEY RAT; STRUCTURE ANALYSIS; VIRUS INFECTION;

ANIMALS; ANTIVIRAL AGENTS; BENZIMIDAZOLES; HELA CELLS; HUMANS; KIDNEY; LIVER; LUNG; MALE; PIPERIDINES; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RESPIRATORY SYNCYTIAL VIRUSES; STRUCTURE-ACTIVITY RELATIONSHIP; TISSUE DISTRIBUTION; VIRAL FUSION PROTEINS;

EID: 34648834114     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm070143x     Document Type: Article

References (23)

1. Andries, K.; Moeremans, M.; Gevers, T.; Willebrords, R.; Sommen, C.; Lacrampe, J.; Janssens, F.; Wyde, P. R. Substituted benzimidazoles with nanomolar activity against respiratory syncytial virus. Antiviral Res. 2003, 60, 209-219.
2. Chanock, R.; Roizman, B.; Myers, R. Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA). I. Isolation, properties and characterization. Am. J. Hyg. 1957, 66, 281-290.
3. Sigurs, N.; Gustafsson, P. M.; Bjarnason, R.; Lundberg, F.; Schmidt, S.; Sigurbergsson, F.; Kjellman, B. Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. Am. J. Respir. Crit. Care Med. 2005, 171, 137-141.
4. Mejias, A.; Chavez-Bueno, S.; Rios, A. M.; Fonseca-Aten, M.; Gomez, A. M.; Jafri, H. S.; Ramilo, O. Asthma and respiratory syncytial virus. New opportunities for therapeutic intervention. Ann. Pediatr. 2004, 61, 252-260.
5. Hall, C. B. Prospects for a respiratory syncytial virus vaccine. Science 1994, 265, 1393-1394.
6. Meijas, A; Ramilo, O. New approaches to reduce the burden of RSV infection. Drug Discovery Today 2006, 3, 173-181.
7. Broughton, S.; Greenough, A. Drugs for the management of respiratory syncytial virus infection. Curr. Opin. Invest. Drugs 2004, 5, 862-865.
8. Ding, W. D.; Mitsner, B.; Krishnamurthy, G.; Aulabaugh, A.; Hess, C. D.; Zaccardi, J.; Cutler, M.; Feld, B.; Gazumyan, A.; Raifeld, Y.; Nikitenko, A.; Lang, S. A.; Gluzman, Y.; O'Hara, B.; Ellestad, G. A. Novel and Specific Respiratory Syncytial Virus Inhibitors That Target Virus Fusion. J. Med. Chem. 1998, 41, 2671-2675.
9. Razinkov, V.; Gazumyan, A.; Nikitenko, A.; Ellestad, G.; Krishnamurthy, G. RFI-641 inhibits entry of respiratory syncytial virus via interactions with fusion protein. Chem. Biol. 2001, 8, 645-659.
10. Douglas, J. L.; Panis, M. L.; Ho, E.; Lin, K. Y.; Krawczyk, S. H.; Grant, D. M.; Cai, R.; Swaminathan, S.; Cihlar, T. Inhibition of respiratory syncytial virus fusion by the small molecule VP-14637 via specific interactions with F protein. J. Virol. 2003, 77, 5054-5064.
11. Cianci, C.; Yu, K. L.; Combrink, K.; Sin, N.; Pearce, B.; Wang, A.; Civiello, R.; Voss, S.; Luo, G.; Kadow, K.; Genovesi, E. V.; Venables, B.; Gulgeze, H.; Trehan, A.; James, J.; Lamb, L.; Medina, I.; Roach, J.; Yang, Z.; Zadjura, L.; Colonno, R.; Clark, J.; Meanwell, N.; Krystal, M. Orally active fusion inhibitor of respiratory syncytial virus. Antimicrob. Agents Chemother. 2004, 48, 413-422.
12. Zhao, X.; Singh, M.; Malashkevich, V. N.; Kim, P. S. Structural characterization of the human respiratory syncytial virus fusion protein core. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 14172-14177.
13. Douglas, J. L.; Panis, M. L.; Ho, E.; Lin, K-Y.; Krawczyk, S. H.; Grant, D. H.; Cai, R.; Swaminathan, S.; Chen, X.; Cihlar, T. Small molecules VP-14637 and JNJ-2408068 inhibit respiratory syncytial virus fusion by similar mechanisms. Antimicrob. Agents Chemother. 2005, 49, 2460-2466.
14. Unpublished data.
15. Preparation of the compounds described in patent application WO2001000611, 2001.
16. Preparation of starting material 32 described in patent application WO2005058873, 2005.
17. http://www.acdlabs.com/products/phys_chem_lab/pka/.
18. Park, C. M. Concise synthesis of 3,7-dioxa-9-aza-bicyclo[3,3,1]-nonane. J. Org. Chem. 2006, 71, 413-415.
19. Avdeef, A. Physicochemical profiling (solubility, permeability, and charge state). Curr. Top. Med. Chem. 2001, 1, 277-351.
20. Yoshida, M.; Kobunai, T.; Aoyagi, K.; Saito, H.; Utsigi, T.; Wierzba, K.; Yamada, Y. Specific distribution of TOP-53 to the lung and lung-localized tumor is determined by its interaction with phospholipids. Clin. Cancer Res. 2000, 6, 4396-4401.
21. Zane, P. A.; Brindle, S. D.; Gause, D. O.; O'Buck, A. J.; Raghavan, P. R.; Tripp, S. L. Physicochemical factors associated with binding and retention of compounds in ocular melanin of rats: Correlations using data from whole-body autoradiography and molecular modeling for multiple linear regression analyses. Pharm. Res. 1990, 7, 935-941.
22. a-DPAS titrator from SIRIUS.
23. Bonfanti, J. F.; et al. J. Med. Chem, 2007, to be submitted for publication.